Comparative study of capecitabine combined with oxaliplatin and S-1 combined with oxaliplatin in the treatment of advanced gastric cancer
Objective To compare the clinical efficacy of capecitabine combined with oxaliplatin and S-1 combined with oxaliplatin in the treatment of advanced gastric cancer. Methods 62 patients with advanced gastric cancer in Yuyao People's hospital were selected as the subjects. The control group of S-1 combined with oxaliplatin in treatment, patients in the experimental group of capecitabine combined with oxaliplatin. The clinical efficacy, adverse reactions and other clinical indicators of the two groups were compared and analyzed. Results After the corresponding treatment, in the experimental group, 3 cases deteriorated, 7 cases were stable, 13 cases were partial remission, and 8 cases were complete remission. In the control group, 4 cases worsened, 8 cases were stable, 12 cases were partial remission, and 7 cases were completely relieved. The effective rate of the control group was 61.29%, the effective rate of the experimental group was 67.74%, and the difference between the two groups was not statistically significant. In the experimental group, diarrhea occurred in 7 cases, nausea and vomiting occurred in 15 cases, and hand foot syndrome in 5 cases. In the control group, 6 cases of hand foot syndrome, 16 cases of nausea and vomiting, and 7 cases of diarrhea. There was no significant difference in adverse reactions between the two groups, and all the patients were tolerant. Conclusion S-1 combined with oxaliplatin and capecitabine combined with oxaliplatin in treatment of advanced gastric cancer effect, are more ideal, high safety, has clinical significance.
capecitabineAsha Leigh PerS-1advanced gastric cancer
NETL
NSTL
万方数据
维普
